Payment overview · 2025
General Payments
$894.50
22 reported records · 16 companies
Healthcare provider profile · identity verified
Stephanie Davis, RN, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · THE WOODLANDS, TX · NPI 1184928921
Verified facts
What the public records show
CMS Open Payments records show Stephanie Davis, RN, FNP received $894.50 in general payments during 2025 across 22 reported records.
Phathom Pharmaceuticals, Inc. accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Mounjaro, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $149.23 | 16.7% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $121.86 | 13.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $116.15 | 13.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $112.12 | 12.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.99 | 9.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $78.03 | 8.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.57 | 5.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.34 | 3.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.42 | 3.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.32 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.70 | 2.3% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $20.23 | 2.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.58 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.88 | 1.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.28 | 1.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $13.80 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $894.50 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $149.23 | 2 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $116.15 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $112.12 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $78.03 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $78.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.30 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $58.30 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 18 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 208 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 123 | 45 |
| Lisinopril | Lisinopril | 116 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 16 |
| Simvastatin | Simvastatin | 55 | 19 |
| Losartan Potassium | Losartan Potassium | 54 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 16 |
| Bupropion Xl | Bupropion Hcl | 40 | 12 |
| Trazodone Hcl | Trazodone Hcl | 40 | 16 |
| Metformin Hcl | Metformin Hcl | 39 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 13 |
| Sertraline Hcl | Sertraline Hcl | 37 | 15 |
| Celecoxib | Celecoxib | 35 | 11 |
| Allopurinol | Allopurinol | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 32 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 30 |
| Metformin Hcl Er | Metformin Hcl | 29 | 14 |
| Alendronate Sodium | Alendronate Sodium | 28 | 14 |
| Gabapentin | Gabapentin | 28 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 28 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 15 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 13 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $894.50 · 22 records | Phathom Pharmaceuticals, Inc. | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Epclusa, Flector, Fluad, Flucelvax, GARDASIL 9, GIVLAARI, Licart, MOUNJARO, NURTEC ODT, PREVNAR 20, SYMPLICITY G3, SYNTHROID, Tirosint, VAXELIS, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error